Analyst points to ChemoCentryx drug's huge potential in vasculitis space

A drug developed by privately-held USA-based biopharma company ChemoCentryx has strong potential to address unmet needs in the vasculitis space, according to an analyst with research and consulting firm GlobalData.

CCX168, an orally administered small molecule in development for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), could be the answer for patients who currently face a prolonged duration of maintenance therapy after remission.

Alexandra Annis, GlobalData's analyst covering immunology, explains: “The majority of those currently diagnosed with AVV achieve remission, but a substantial risk of relapse means that they face a prolonged duration of maintenance therapy, resulting in long-term exposure to therapies with significant side effects. Long exposure to Rituxan (rituximab) or methotrexate, for example, is associated with significant side effects and must be administered in conjunction with glucocorticoids (GC).”